Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 3/20 | 0.42 |
| ▸ | KIT | P10721 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377779 | 0.85 | KMT2A (0.52) | MEN1KMT2AALOX15CSF1RKIT | |
| SCHEMBL3326516 | 0.82 | MEN1 (0.65) | MEN1KMT2AALOX15MAPTPDE4B | |
| SCHEMBL913132 | 0.77 | TYK2 (0.48) | MEN1KMT2ATYK2SYKBRSK1 | |
| SCHEMBL425279 | 0.77 | MAPT (0.46) | MEN1KMT2AALOX15TYK2SYK | |
| SCHEMBL425280 | 0.77 | MAPT (0.46) | MEN1KMT2AALOX15TYK2SYK | |
| SCHEMBL10195923 | 0.77 | MAPT (0.46) | MEN1KMT2AALOX15TYK2SYK | |
| SCHEMBL13060564 | 0.77 | MEN1 (0.40) | MEN1KMT2AALOX15TYK2SYK | |
| SCHEMBL1373842 | 0.76 | MEN1 (0.52) | MEN1KMT2AALOX15CSF1RKIT | |
| SCHEMBL3322289 | 0.76 | MEN1 (0.60) | MEN1KMT2AALOX15MAPTPDE4B | |
| SCHEMBL13814006 | 0.76 | MAPT (0.41) | MEN1KMT2AALOX15TYK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-7851466-B2 | Pyrimidine compounds and uses thereof | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7465725-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1827447-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | Synta Pharmaceuticals Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7067514-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135518-A1 | Pyrimidine compounds and uses thereof | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006060194-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | WO | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20060025409-A1 | e.g. N-{2-[3-(3,4-dimethoxy-phenyl)-propyl]-6-morpholin-4-yl-pyrimidin-4-yl}-N'-(1H-indol-3-ylmethylene)-hydrazine; interleukin-12 antagonist; antiinflammatory, antidiabetic agent; rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus | SYNTA PHARMACEUTICALS CORP. (US) | 2006-02-02 | — | — | US | disclosed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025409-A1 | e.g. N-{2-[3-(3,4-dimethoxy-phenyl)-propyl]-6-morpholin-4-yl-pyrimidin-4-yl}-N'-(1H-indol-3-ylmethylene)-hydrazine; interleukin-12 antagonist; antiinflammatory, antidiabetic agent; rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus | RORC, NR2C2, OSTC | MEN1 4523/4885KMT2A 3925/4885ALOX15 1039/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | MEN1 149/4885KMT2A 2431/4885ALOX15 3088/4885 |
| US-20060135518-A1 | Pyrimidine compounds and uses thereof | RORC, IL23R, ORC3 | MEN1 4832/4885KMT2A 4060/4885ALOX15 1042/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MEN1 149/4885KMT2A 2431/4885ALOX15 3088/4885 |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | RORC, IL23R, ORC3 | MEN1 4837/4885KMT2A 4103/4885ALOX15 892/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MEN1 4719/4885KMT2A 2347/4885ALOX15 2942/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MEN1 4656/4885KMT2A 2687/4885ALOX15 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.